David Kirn Sells 114,746 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 114,746 shares of the stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $10.47, for a total value of $1,201,390.62. Following the completion of the sale, the insider owned 942,485 shares of the company’s stock, valued at $9,867,817.95. This trade represents a 10.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

David Kirn also recently made the following trade(s):

• On Monday, June 1st, David Kirn sold 1,922 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.02, for a total value of $19,258.44.

4D Molecular Therapeutics Price Performance

NASDAQ:FDMT opened at $11.62 on Thursday. The business’s 50-day simple moving average is $9.50 and its 200-day simple moving average is $9.13. 4D Molecular Therapeutics, Inc. has a fifty-two week low of $3.68 and a fifty-two week high of $12.34. The stock has a market capitalization of $607.49 million, a PE ratio of -4.52 and a beta of 2.75.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The business had revenue of $3.05 million for the quarter, compared to the consensus estimate of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. On average, research analysts expect that 4D Molecular Therapeutics, Inc. will post -3.8 earnings per share for the current year.

Wall Street Analysts Forecast Growth

FDMT has been the subject of several research reports. Chardan Capital reissued a “buy” rating and set a $26.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday, March 19th. Wall Street Zen cut shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $21.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research note on Monday, March 30th. Royal Bank Of Canada increased their target price on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the stock an “outperform” rating in a report on Thursday, March 19th. Finally, HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $29.88.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several hedge funds have recently made changes to their positions in FDMT. RA Capital Management L.P. raised its holdings in shares of 4D Molecular Therapeutics by 23.9% in the fourth quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock valued at $42,399,000 after purchasing an additional 1,090,000 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in 4D Molecular Therapeutics by 13.2% during the first quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock worth $48,868,000 after purchasing an additional 611,276 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in 4D Molecular Therapeutics by 4.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 4,302,905 shares of the company’s stock worth $32,272,000 after purchasing an additional 174,489 shares during the last quarter. State Street Corp grew its position in 4D Molecular Therapeutics by 197.5% in the fourth quarter. State Street Corp now owns 2,688,880 shares of the company’s stock valued at $20,167,000 after purchasing an additional 1,785,106 shares in the last quarter. Finally, Armistice Capital LLC grew its position in 4D Molecular Therapeutics by 76.6% in the fourth quarter. Armistice Capital LLC now owns 1,936,000 shares of the company’s stock valued at $14,520,000 after purchasing an additional 840,000 shares in the last quarter. 99.27% of the stock is owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.